SCHEMBL5457430

SCHEMBL5457430

Cc1cc(C(=O)N2CCOCC2)cc2c(Nc3cccc4c3CCO4)c(C(N)=O)cnc12

nearest known ligand 0.55

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
PDE4B Q07343 3/20 0.55
CSF1R P07333 3/20 0.46
CAMK1D Q8IU85 3/20 0.40
GAA P10253 2/20 0.39
MAPT P10636 2/20 0.39
KDM4E B2RXH2 1/20 0.39
RAB9A P51151 1/20 0.39
CYP3A4 P08684 1/20 0.38
CYP2C9 P11712 1/20 0.38
CNR1 P21554 2/20 0.38
CNR2 P34972 2/20 0.38
MAPK1 P28482 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
LRRK2 Q5S007 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5405232 0.93 PDE4B (0.54) PDE4BCSF1RCYP3A4CYP2C9
SCHEMBL5404792 0.90 PDE4B (0.51) PDE4BCSF1RCAMK1DCYP3A4CYP2C9
SCHEMBL5399007 0.88 PDE4B (0.53) PDE4BCSF1RCAMK1D
SCHEMBL5413089 0.88 PDE4B (0.49) PDE4BCSF1RCYP3A4CYP2C9
SCHEMBL4928496 0.87 PDE4B (0.54) PDE4BCSF1RCAMK1DCYP3A4CYP2C9
SCHEMBL5763422 0.85 PDE4B (0.57) PDE4BCSF1R
SCHEMBL5763692 0.85 PDE4B (0.54) PDE4BCSF1RCNR2
SCHEMBL4627105 0.84 PDE4B (0.61) PDE4BGAAMAPTKDM4ECYP3A4
SCHEMBL31020770 0.83 PDE4B (0.61) PDE4BCSF1R
SCHEMBL8305598 0.82 PDE4B (0.54) PDE4BCSF1RRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070191426-A1 Derivatives of 3-aminocarbonylquinoline, pharmaceutical compositions containing them and processes and intermediates for their preparation GLAXO GROUP LIMITED (GB) 2007-08-16 US claimed
US-20070191426-A1 Derivatives of 3-aminocarbonylquinoline, pharmaceutical compositions containing them and processes and intermediates for their preparation GLAXO GROUP LIMITED (GB) 2007-08-16 US disclosed
EP-1673345-A1 DERIVATIVES OF 3-AMINOCARBONYLQUINOLINE, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND PROCESSES AND INTERMEDIATES FOR THEIR PREPARATION GLAXO GROUP LIMITED (GB) 2006-06-28 EP disclosed
WO-2005030725-A1 DERIVATIVES OF 3-AMINOCARBONYLQUINOLINE, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND PROCESSES AND INTERMEDIATES FOR THEIR PREPARATION GLAXO GROUP LIMITED (GB) 2005-04-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070191426-A1 Derivatives of 3-aminocarbonylquinoline, pharmaceutical compositions containing them and processes and intermediates for their preparation PDE4B, PDE4A, PDE3B PDE4B 1/4885CSF1R 3981/4885CAMK1D 2595/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.